We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.
- Authors
Onoue, Masahide; Terada, Tomohiro; Okuda, Masahiro; Fujimoto, Koji; Doi, Ryuichiro; Imamura, Masayuki; Inui, Ken-ichi
- Abstract
Background. Gemcitabine hydrochloride (GEM) is one of the most effective chemotherapeutic agents for pancreatic cancer; however, factors affecting GEM-induced leukopenia have not been clarified yet. In the present study, we analyzed the relationship between patients' backgrounds and GEM-induced leukopenia. Methods; Thirty-eight patients with pancreatic cancer were analyzed for correlation between the dose of GEM and the blood leukocyte number. Moreover, we compared leukopenia in resected and non-resected patients. Results. The incidence of grade 3 or 4 leukopenia was 25% in the non-resected patients, whereas equivalent leukopenia was observed in 57% of the resected patients (P = 0.048 by the &chi2 test). The relative decrease in blood leukocytes induced by GEM administration was more severe in resected patients (41.3 ± 9.9%), as compared to non- resected patients (52.6 ± 16.0%; P = 0.023 by t-test). Conclusion. In the present study, we found that the administration of GEM to patients after surgical resection caused more severe leukopenia, as compared to findings in non-resected patients. These data suggested that more frequent monitoring of the leukocyte count and prolonged intervals between GEM administrations are necessary for resected patients with pancreatic cancer.
- Subjects
PANCREAS; CANCER; CANCER treatment; CANCER patients; CANCER chemotherapy; SURGERY
- Publication
International Journal of Clinical Oncology, 2004, Vol 9, Issue 3, p174
- ISSN
1341-9625
- Publication type
Article
- DOI
10.1007/s10147-004-0393-5